ASHP urged the Health Resources and Services Administration (HRSA) to abandon attempts to launch a rebate model for the 340B Drug Pricing Program.
“The 340B program is foundational to our nation’s healthcare system,” said Tom Kraus, ASHP vice president of government relations. "Undercutting it with an ill-advised rebate program places patient services at risk."
ASHP outlined the detrimental impacts of a rebate model in comments submitted this week to HRSA. We also shared model comments with state affiliates and health systems to support their outreach to HRSA.
ASHP highlighted that the rollout of Inflation Reduction Act (IRA) rebates is already proving complex and inefficient, with delayed payments, significant administrative strain, and millions in outstanding rebates in just the first few months. Those costs could be even larger if the 340B program adopts a rebate model.
"As demonstrated by the poorly designed IRA rebate rollout, rebate programs benefit manufacturers at the expense of patients and providers," said Kraus.
ASHP remains committed to safeguarding the 340B program for our patients and will continue to keep members informed about ongoing litigation and our aggressive advocacy efforts to safeguard this critical program.
